在ADPKD中增强托尔瓦普坦耐受性:低剂量甲酸可以改善患者的幸福感,而不会影响疗效 - - 一个案例报告
Kristiana Kola1, Martina Catania1, Liliana Italia De Rosa1
1Vita Salute San Raffaele University, 20132 Milan, Italy.
甲酸可以通过减少过度排尿和口渴等副作用来改善自身主导多囊性病 (ADPKD) 患者对托尔瓦普坦的耐受性. 这种组合疗法在ADPKD管理中有望改善生活质量.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 自体主导多囊性病 (ADPKD) 是一种常见的遗传性病,其特征是囊形成和功能下降.
- PKD1/PKD2基因的突变和抗尿激素 (ADH) 的升高驱动了囊的生长,托尔瓦普坦是唯一批准的治疗方法.
- 托尔瓦普坦有效减缓ADPKD的进展,但通常会导致显著的多尿和口渴,影响患者的生活质量.
更多相关视频
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
07:35Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Thiazide-Class Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
